Voyager Acquisition Corp/cayman Islands Form 4 insider transactions

VERAXA Biotech AG shareholders have approved the merger with Veraxa Biotech Holding AG and the issuance of new shares to Voyager Acquisition Corp., moving closer to a NASDAQ listing.

Voyager Acquisition Corp. and Veraxa Biotech AG amended their business combination agreement, increasing the merger consideration to $1.35 billion and adjusting sponsor share forfeitures.

Voyager Acquisition Corp. and Veraxa Biotech AG amended their Business Combination Agreement, extending the merger completion deadline to August 7, 2026, and modifying termination fee provisions.

VERAXA Biotech and Secarna Pharmaceuticals announce a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and inflammatory diseases.

Voyager Acquisition Corp. announces a definitive business combination agreement with Veraxa Biotech AG, valuing the combined entity at approximately $1.5 billion.

VERAXA Biotech and Voyager Acquisition Corp. announced the filing of a Form F-4 Registration Statement with the SEC, marking a key step towards their proposed business combination and VERAXA's public listing.

Voyager Acquisition Corp. has entered into a Joinder Agreement, bringing Veraxa Biotech Holding AG and Veraxa Cayman Merger Sub into the previously announced Business Combination Agreement with Veraxa Biotech AG, formalizing the merger structure.

VERAXA Biotech, the proposed de-SPAC target of Voyager Acquisition Corp., announced its attendance at major industry conferences to highlight its BiTAC technology and growth plans, following the signing of a definitive business combination agreement.

VERAXA Biotech, a proposed de-SPAC acquisition target of Voyager Acquisition Corp., partners with OmniAb to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.

Voyager Acquisition Corp. and Veraxa Biotech AG have announced a definitive business combination agreement, valuing Veraxa at $1.3 billion, to create a Nasdaq-listed biopharmaceutical company focused on next-generation cancer therapies.

Voyager Acquisition Sponsor Holdco LLC reports acquiring 5,037,500 Private Placement Warrants in Voyager Acquisition Corp.

Adeel Rouf, CEO of Voyager Acquisition Corp., reports the acquisition of 5,037,500 Private Placement Warrants.